Inari Medical, Inc. (NASDAQ:NARI) Director Rebecca Chambers Sells 260 Shares

Inari Medical, Inc. (NASDAQ:NARI) Director Rebecca Chambers sold 260 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $45.99, for a total transaction of $11,957.40. Following the completion of the transaction, the director now owns 9,684 shares of the company’s stock, valued at approximately $445,367.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Rebecca Chambers also recently made the following trade(s):

• On Monday, May 20th, Rebecca Chambers sold 964 shares of Inari Medical stock. The shares were sold at an average price of $45.39, for a total transaction of $43,755.96.

Inari Medical Trading Down 0.0 %

Shares of NASDAQ NARI opened at $45.98 on Tuesday. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $71.85. The company has a 50-day simple moving average of $44.57 and a 200-day simple moving average of $50.86.

Inari Medical (NASDAQ:NARI) last issued its quarterly earnings results on Tuesday, April 30th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.15). Inari Medical had a negative return on equity of 1.65% and a negative net margin of 4.54%. The firm had revenue of $143.19 million for the quarter, compared to analysts’ expectations of $138.32 million. As a group, analysts expect that Inari Medical, Inc. will post -0.41 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Canaccord Genuity Group dropped their target price on shares of Inari Medical from $75.00 to $55.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Truist Financial dropped their target price on shares of Inari Medical from $61.00 to $52.00 and set a “hold” rating for the company in a report on Friday, March 22nd. Wells Fargo & Company dropped their target price on shares of Inari Medical from $100.00 to $84.00 and set an “overweight” rating for the company in a report on Wednesday, May 1st. Piper Sandler dropped their target price on shares of Inari Medical from $55.00 to $50.00 and set a “neutral” rating for the company in a report on Wednesday, May 1st. Finally, Needham & Company LLC dropped their target price on shares of Inari Medical from $72.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, May 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $65.71.

Institutional Investors Weigh In On Inari Medical

Several hedge funds have recently modified their holdings of NARI. Vanguard Group Inc. boosted its position in shares of Inari Medical by 11.1% in the first quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock worth $268,681,000 after acquiring an additional 561,562 shares during the last quarter. Norges Bank acquired a new stake in shares of Inari Medical in the fourth quarter worth approximately $29,491,000. Brown Advisory Inc. boosted its position in shares of Inari Medical by 17.6% in the fourth quarter. Brown Advisory Inc. now owns 1,702,113 shares of the company’s stock worth $110,501,000 after acquiring an additional 255,182 shares during the last quarter. First Light Asset Management LLC acquired a new stake in shares of Inari Medical in the first quarter worth approximately $10,265,000. Finally, Clearbridge Investments LLC acquired a new stake in shares of Inari Medical in the fourth quarter worth approximately $11,479,000. 90.98% of the stock is owned by institutional investors and hedge funds.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.